Likely EU rejection of Biogen's Alzheimer's drug comes as no surprise, says dementia researcher
The negative opinion from a trend vote from the EMA's expert committee, the CHMP, was to be expected, says director of clinical trial unit at the Danish Dementia Research Center. The FDA, not the EMA, has been the outlier in common approval practices.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
It is in the cards, and thus should come as no big surprise, that the pharmaceutical company Biogen is very likely to receive the European thumbs-down for its Alzheimer's drug, Aduhelm (aducanumab).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Biogen's Alzheimer's drug Aduhelm faces EU rejection
For subscribers
